
Intodna S.A.
Research and experimental development in natural sciences and engineering
Overview
Intodna offers DNA damage detection and analysis of DNA repair biology using the STRIDE® platform. The company provides single-cell resolution and AI-driven data analysis. It serves pharmaceutical companies, biotechs, and research laboratories.
Financials
Revenue history (in k)
Financial insight
- The statement flags a going concern risk. Opis znajduje się w Informacji Dodatkowej w nocie nr 19 "Informacja dotycząca założenia kontynuacji działalności"
Filing timeliness
3 of 5 financial statements were filed late (the longest delay 101 days for 2021). All were audited by a statutory auditor.
- 202508/07/2026
- 202408/07/2025
- 202305/08/2024
- 202228/07/2023
- 202124/10/2022
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.
Results vs industry
News

intoDNA awarded funding through Fundusze Europejskie dla Małopolski (FEM) 2021–2027 to build a new, automated R&D laboratory
intoDNA awarded funding through Fundusze Europejskie dla Małopolski (FEM) 2021–2027 to build a new, automated R&D laboratory

intoDNA Presents Data on Two Novel Assays, sSTRIDE-NER and sSTRIDE-PARP1, in Poster Presentations at the 2026 AACR Annual Meeting
intoDNA Presents Data on Two Novel Assays, sSTRIDE-NER and sSTRIDE-PARP1, in Poster Presentations at the 2026 AACR Annual Meeting
intoDNA to Present Two Poster Presentations at the 2026 AACR Annual Meeting
– intoDNA to Present Two Poster Presentations at the 2026 AACR Annual Meeting –
intoDNA Forms Strategic Advisory Board with Leading Diagnostics and Precision Oncology Experts
– New board to accelerate the STRIDE® platform, revolutionizing DNA damage and repair diagnostics for precision oncology –

intoDNA Honored with the 2025 Supplier Recognition Award by Scientist.com
We are pleased to share that intoDNA has been honored with the 2025 Supplier Recognition Award by Scientist.com, a leading global R&D sourcing platform.

intoDNA Expands Leadership Team with Appointment of Maggie Rougier-Chapman as Chief Business Officer
– Appointment initiates U.S. expansion as STRIDE® scales biopharma services and progresses toward diagnostic readiness –
Industry
Offer
- DNA damage detection
- Functional DNA repair assays
- Laboratory assay development
- Biomarker development
- Confocal imaging
- Biological data analysis
Websites
- intodna.comWhere DNA Breaks, Our Insight Begins – intoDNAWordPress 7.1Google Tag ManagerYoast SEOCloudflareLLiteSpeed
Job offers
The company lists 3 job openings on its own careers page: intodna.com/careers.
Authorized Representatives
Manner of representation
Each member of the management board acting independently is authorised to submit declarations of will concerning property rights and obligations and to sign on behalf of the company, provided that joint action by two members of the management board acting jointly is required to incur obligations or dispose of a right in an amount equal to or exceeding PLN 250,000.00 (two hundred and fifty thousand zlotys).
Supervisory board
Beneficial owners
| Person | Rights |
|---|---|
Sanctions and PEP
Sanctions
No matches (EU, UN, US, UK, MSWiA, World Bank)
PEP
No matches
Bank accounts
Registered as a VAT taxpayer on 2017-12-22.
67 1750 0012 0000 0000 4118 7328
68 1750 0012 0000 0000 3853 3584
41 1750 0012 0000 0000 4001 4969
Debt
No entries in the National Debtors Register (KRZ).
Public aid
10 public aid cases recorded, with a total value of $2,347,134.
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Mar 27, 2025 | De minimis aid (in accordance with Commission Regulation 2023/2831) | $306K$306,028 | Marszałek Województwa Małopolskiego | |
| Mar 27, 2025 | Regional investment aid | $258.1K$258,112 | Marszałek Województwa Małopolskiego | |
| Jun 13, 2024 | De minimis aid (in accordance with Commission Regulation 2023/2831) | $8,018$8,018 | Prezes Banku Gospodarstwa Krajowego |
European Funds
| Start | Project | EU co-financing | Programme | |
|---|---|---|---|---|
| 2024-12-01 | Development and implementation of a new method for the direct detection and measurement of replication stress in human cells and tissues | $1.6M$1,559,662 | European Funds for a Modern Economy | |
| 2024-09-01 | Investment in expanding the laboratory infrastructure of INTODNA S.A. to carry out R&D work aimed at developing a new diagnostic technology for identifying and measuring phenomena occurring during DNA replication | $562.9K$562,867 | European Funds for Małopolska 2021-2027 | |
| 2021-02-18 | Implementation of research and development work to commence providing clinical research support services for new cancer therapies. | $207.1K$207,103 | Operational Programme Smart Growth |
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
| BDO register entry | Active |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Sieć Badawcza Łukasiewicz - Krakowski Instytut Technologiczny Research institute | $12,349,183.25 | iod.krakow.pl | ||
| Energotest sp. z o.o. | $2,282,961.01 | entest.pl | ||
| Ultrarent sp. z o.o. | $2,276,522.05 | ultrarent.pl | ||
| Baltictest sp. z o.o. | $1,563,892.44 | baltictest.pl | ||
| Aslab Science P.S.A. | $1,504,132.17 | aslabsci.com | ||
| Scope Fluidics S.A. | $1,264,188.85 | scopefluidics.com | ||
| Alcid sp. z o.o. | $1,230,813.28 | alcid.pl | ||
| Śląski Park Technologii Medycznych Kardio-Med Silesia sp. z o.o. | $969,037.30 | kmptm.pl | ||
| Nanogroup S.A. | $843,099.47 | nanogroup.eu | ||
| Precisionlife Poland sp. z o.o. | $617,020.34 | precisionlife.com |
Change history
| Date | Event | |
|---|---|---|
| 2026-05-05 | Share capital increase (107,431.35 PLN → 108,130.10 PLN) | |
| 2025-09-05 | Share capital increase (100,000.00 PLN → 107,431.35 PLN) | |
| 2020-12-31 | Entered in the register |
FAQ
Last updated: 2026-07-15